Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21551624 | 0.88 | MEN1 (0.56) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL26516645 | 0.87 | MEN1 (0.54) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL21551286 | 0.87 | MEN1 (0.54) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1268074 | 0.85 | MEN1 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL21551330 | 0.85 | SMN1; SMN2 (0.56) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL3970912 | 0.84 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL379160 | 0.84 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL4814264 | 0.84 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL7393652 | 0.84 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL5101300 | 0.83 | MEN1 (0.59) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2016-02-18 | — | — | US | disclosed |
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2611784-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | Amgen, Inc (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012018668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | MEN1 1707/4885KMT2A 493/4885NPSR1 4833/4885 |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | MEN1 1707/4885KMT2A 493/4885NPSR1 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.